Prakt. lékáren. 2018; 14(1): 12-15 | DOI: 10.36290/lek.2018.056

Agomelatine for treating depression in somatic diseases

Sylva Racková
Psychiatrická ambulance, Plzeň

A large proportion of patients treated for depression also suffer from somatic diseases. It is often difficult to choose an appropriateantidepressant drug while preventing deterioration of the patient’s physical condition and avoiding drug interactions. Agomelatineis a highly effective antidepressant with very low rates of adverse effects and drug interactions. It appears to be a suitableoption in patients with cardiovascular, neurological, and metabolic disorders.

Keywords: agomelatine, depression, cardiovascular disease, diabetes, neurology, interaction

Received: May 14, 2018; Accepted: May 14, 2018; Published: March 24, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S. Agomelatine for treating depression in somatic diseases. Praktické lékárenství. 2018;14(1):12-15. doi: 10.36290/lek.2018.056.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Švestka J. Agomelatin - melatoninové a noradrenalinové/dopaminové antidepresivum: syntéza starších a novějších poznatků. Farmakoterapie 2012; Suppl 3.
    2. Švestka J, Mohr P. Agomelatin, melatoninové a noradrenalinové/dopaminové antidepresivum-mechanismus účinku a klinické důsledky. Farmakoterapie 2012; 8(3): 256-263.
    3. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348: 1888. Go to original source... Go to PubMed...
    4. Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 2015; 29(8): 695-712. Go to original source... Go to PubMed...
    5. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011; 26(8): 537-542. Go to original source... Go to PubMed...
    6. Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 2010; 25(3): 222-229. Go to original source... Go to PubMed...
    7. Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep 2017; 19(9): 63. Go to original source... Go to PubMed...
    8. Novick D, Hong J, Montgomery W, Due?as H, Gado M, Haro JM. Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study. Neuropsychiatr Dis Treat 2015; 11: 197-205. Go to original source...
    9. Markkula N, Härkänen T, Nieminen T, Pe?a S. Prognosis of depressive disorders in the general population-results from the longitudinal Finnish Health 2011 Study. JAD 2016; 190: 687-696. Go to original source... Go to PubMed...
    10. Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother 2014; 14(5): 539-551. Go to original source... Go to PubMed...
    11. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75(5): e441-449. Go to original source... Go to PubMed...
    12. Donazzolo Y, Latreille M, Caillaud MA, Mocaer E, Seguin L. Evaluation of the effects of therapeutic and supratherapeutic doses of agomelatine on the QT/QTc interval: a phase I, randomized, double-blind, placebo-controlled and positive-controlled, crossover thorough QT/QTc study conducted in healthy volunteers. J Cardiovasc Pharmacol. 2014; 64(5): 440-451. Go to original source... Go to PubMed...
    13. Chernyaeva MS, Shimohina NY, Petrova MM, Savchenko AA, Kaskaeva DS. Influence Agomelatine Therapy on Hemostasis of patients with acute Myocardial infarction, Clinical Therapeutics 2015; 37: 8S Go to original source...
    14. Medvedev VE. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE. Neuropsychiatr Dis Treat 2017; 13: 1141-1151. Go to original source... Go to PubMed...
    15. Karaiskos D, Tzavellas E, Ilias I, Liappas I, Paparrigopoulos T. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. Int J Clin Pract 2013; 67(3): 257-260. Go to original source... Go to PubMed...
    16. Kumar K, Salman MT, Shukla V, Ahmad A, Verma VK, Rizvi DA, Kohli A. Comparative Effect of Agomelatine versus Escitalopram on Glycemic Control and Symptoms of Depression in Patients with Type 2 Diabetes Mellitus and Depression. JPSR 2015; 6(10): 4304-4309.
    17. Kang R, He Y, Yan Y, Li Z, Wu Y, Guo X, Liang Z, Jiang J. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatr Dis Treat 2015; 27(11): 1307-1311. Go to original source...
    18. Tchekalarova J, Petkova Z, Pechlivanova D, Moyanova S, Kortenska L, Mitreva R, Lozanov V, Atanasova D, Lazarov N, Stoynev A. Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage, and behavioral changes in a kainate model of temporal lobe epilepsy. Epilepsy Behav 2013; 27(1): 174-187. Go to original source... Go to PubMed...
    19. Aguiar CC, Almeida AB, Araújo PV, Vasconcelos GS, Chaves EM, do Vale OC, Mac?do DS, Leal LK, de Barros Viana GS, Vasconcelos SM. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol 2013; 33(6): 825-835. Go to original source... Go to PubMed...
    20. Aguiar CC, Almeida AB, Araújo PV, Vasconcelos GS, Chaves EM, do Vale OC, Mac?do DS, de Sousa FC, Viana GS, Vasconcelos SM. Anticonvulsant effects of agomelatine in mice. Epilepsy Behav 2012; 24(3): 324-328. Go to original source... Go to PubMed...
    21. Vimala PV, Bhutada PS, Patel FR. Therapeutic potential of agomelatine in epilepsy and epileptic complications. Med Hypotheses 2014; 82(1): 105-110. Go to original source... Go to PubMed...
    22. Avila A, Cardona X, Martin-Baranera M, Leon L, Caballol N, Millet P, Bello J. Agomelatine for Depression in Parkinson Disease: Additional Effect on Sleep and Motor Dysfunction J Clin Psychopharmacol 2015; 35(6): 719-723. Go to original source... Go to PubMed...
    23. Pescosolido a kol. Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients. Ophthalmic Physiol Opt 2015; 35(2): 201-205. Go to original source... Go to PubMed...
    24. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-Induced Liver Injury: A Review for Clinicians. Am J Psychiatry 2014; 171(4): 404-415. Go to original source... Go to PubMed...
    25. Gahr M, Kratzer W, Fuchs M, Connemann BJ. Safety and tolerability of agomelatine: focus on hepatotoxicity. Curr Drug Metab 2014; 15(7): 694-702. Go to original source... Go to PubMed...
    26. Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 2015; 3(1): 4. Go to original source... Go to PubMed...
    27. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012; 27(10): 3736-3745. Go to original source... Go to PubMed...
    28. EMA souhrn údajů o přípravku: SPC přípravku Valdoxan: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf
    29. European Medicines Agency. Valdoxan (agomelatine). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d124.
    30. Kořístková B, Grundmann M. Lékové interakce antiepileptik. Část 1. - vzájemné interakce mezi antiepileptiky. Klin Farmakol Farm 2016; 30(4): 19-23. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.